Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · IEX Real-Time Price · USD
3.160
-0.310 (-8.93%)
At close: Apr 18, 2024, 4:00 PM
3.310
+0.150 (4.75%)
Pre-market: Apr 19, 2024, 7:29 AM EDT
Company Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Daniel J. O'Connell M.B.A. |
Contact Details
Address: 427 Park St. Charlottesville, Virginia 22902 United States | |
| Phone | 925-368-8508 |
| Website | acumenpharm.com |
Stock Details
| Ticker Symbol | ABOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001576885 |
| CUSIP Number | 00509G209 |
| ISIN Number | US00509G2093 |
| Employer ID | 36-4108129 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel J. O'Connell M.B.A. | Chief Executive Officer and Director |
| Matt Zuga | Chief Financial Officer and Chief Business Officer |
| Derek M. Meisner Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. James Doherty Ph.D. | President and Chief Development Officer |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Russell Barton M.S. | Chief Operating Officer |
| Kelly Carranza | Vice President, Finance and Accounting and Corporate Controller |
| Alex Braun M.B.A. | Vice President and Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 19, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 1, 2024 | 8-K | Current Report |
| Jan 24, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 19, 2024 | 144 | Filing |